March 11, 2024
DurAVR® Biomimetic THV: Results from the First-in-Human & US Early Feasibility Studies
At CRT 2024, Dr Rishi Puri presented an update on DurAVR® THV. The biomimetic valve is showing consistently promising hemodynamic performance—measured by EOA, MPG, and DVI—from 30 days through 1 year. Learn about DurAVR® THV and view the full presentation on the EFS and FIH studies below.